ArticleJournal of human genetics2026
Development of a zebrafish model of Loeys-Dietz syndrome through tgfbr2b knockdown.
Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preclinical modeling of Loeys-Dietz syndrome: insights into mechanisms and therapy.Orphanet journal of rare diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Loeys-Dietz syndrome (LDS), an autosomal dominant connective tissue disorder, was initially considered "atypical" Marfan syndrome (MFS). MFS is caused by mutations in FBN1 encoding fibrillin 1, which binds to transforming growth factor β (TGF-β) to inhibit it from binding to TGF-β receptors. In contrast, LDS is caused by mutations in TGF-β-related genes, including TGFBR2. Some clinical symptoms of LDS, including cardiovascular and skeletal complications, are similar to those observed in MFS; however, arterial tortuosity and widespread aortic aneurysm, hypertelorism, and cleft palate or bifida uvula are specific to LDS. Therefore, the role and difference of the TGF-β signaling pathway in LDS remains unclear. To elucidate the pathological mechanisms of LDS and the phenotypical differences between MFS and LDS, an LDS zebrafish model was established by knocking down tgfbr2b using an antisense morpholino oligonucleotide (tgfbr2b morphant), and the phenotype and expression of genes and proteins related to the TGF-β signaling pathway were investigated. tgfbr2b morphants presented with a dysmorphic face, bent body, and cardiovascular abnormalities, some of which were similar to those observed in patients with LDS. The TGF-β1 gene and protein expression, as well as the genes related to the BMP signaling pathway, were upregulated, and the smad1/5/9 protein exhibited enhanced phosphorylation. These results suggest that dysregulation of BMP signaling during development plays an essential role in the craniofacial dysmorphism and cardiac abnormalities observed in the LDS zebrafish model. Our study clarified the differences of pathological mechanism between MFS and LDS.
Indexed as
Identifiers
41629640What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.